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A B S T R A C T
Gaucher’s disease (GD) has variable presentations, but cardiac involvement is a generally uncommon clinical mani-
festation of the disease. In the past 25 years, the underlying genetic disorder in GD has been well characterized, with al-
most 300 mutations identified in the glucocerebrosidase gene (GBA). Nevertheless, clear genotype-phenotype correlations
have been confirmed only for the most frequent mutations. We present a female patient, who was known to have aortic
valve pathology from the age of 30. Despite medical follow up, at the age of 60 she presented with heart failure (NYHA
III). At that time echocardiography showed severe fibrosed aortic valve stenosis. Valvuloplasty was planned, when
thrombocytopenia, previously considered to be autoimmune, became severe. Anemia and leukopenia were also noted.
Moderate splenomegaly and severe bone marrow infiltration were found on MRI. Bone marrow aspiration revealed typi-
cal Gaucher cells and the enzyme activity assay confirmed the diagnosis. DNA investigation showed that the patient is
homozygous for the G377S mutation. To our knowledge, of all mutations identified so far, only homozygosity for the
D409H mutation has been associated with cardiovascular valvular disease in patients with a rare type 3c GD. G377S,
found in our patient, is a rare mutation, previously reported as a 'mild’ mutation, because of the finding that homoallelic
patients were essentialy asymptomatic or had mild disease. Our patient, also homozygous for G377S mutation, had a se-
vere form of type 1 GD, with rare cardiac valve involvement, which is a previously unreported clinical presentation for
this mutation. This case further proves that patients with the same genotypes can have different phenotypes, emphasizing
the influence of other genetic and/or environmental factors.
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Introduction
Gaucher’s disease (GD), described for the first time in
18821 is the most prevalent lysosome storage disorder2,
with highest prevalence in Askhenazi Jews, about 1/855,
compared to 1/100,000 in other populations3,4. Inherited
in an autosomal recessive way, this defect of the lysoso-
mal enzyme glucocerebrosidase leads to glucocerebroside
accumulation in the reticuloendothelial system5. Clini-
cally, it is a multisystemic disease, with variable expres-
sion, generally characterized with hepatosplenomegaly,
anemia, thrombocytopenia, bone lesions and sometimes
involvement of lungs, which occur in all types of GD5.
The presence and severity of neurological symptoms
distinguish 3 clinical types of GD6; type 1 (non-neuro-
nopathic), which contributes for 95% of cases, type 2
(acute neuronopathic), characterized with early onset
and survival of up to only 2 years, and type 3 (chronic
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neuronopathic), with infantile or juvenile onset and sur-
vival into adulthood7. Over time it has become clear that
GD patients can have disease manifestations on a contin-
uum of clinical expressions (i.e. different phenotypes),
ranging from only a few signs or laboratory abnormali-
ties on one end of the spectrum to the very severe forms
of the disease on the other8.
Gaucher’s disease is caused by mutation in the gluco-
cerebrosidase (GBA) gene, which was mapped to 1q21.
Almost 300 unique mutations have been reported so far
in the GBA gene9. In non-Jewish population the most
common mutations are L444P and N370S10. Generally,
GD-causing mutations are classified as mild, severe or
null alleles11. The presence of a mild mutation protects
from neurological involvement and leads to a type 1 of
GD, even in combination with a null allele or a severe
mutation. The neuronopathic formes of GD are due to se-
vere mutation homozygosity or the severe mutation and
a null allele combination. The well known genotype-phe-
notype correlation predicts that the N370S (mild muta-
tion) protects from neurological symptoms (type 1 GD)12,13,
as well as homozygosity for L444P (severe mutation) pre-
dicts chronic neuronopathic form (type 3 GD)14–17. De-
spite the genotype-phenotype correlation, a variable ex-
pression of clinical symptoms is present in patients with
the same genotype, indicating that other factors, genetic
and/or enviromental, influence the phenotype18.
Cardiac involvement is a generally uncommon mani-
festation of the disease. Valvular calcifications19–21, con-
strictive pericarditis22,23 and infiltration of ventricular
myocardium24–27 have been reported so far.
Case Report
We report a female patient, with unremarkable family
history and no previous medical history until the age of
30, when she presented with exertional dyspnea and syn-
cope. Physical examination at that time revealed only ab-
normal heart sounds – murmurs compatible with aortic
valve insufficiency. During next years of cardiological fol-
low up, echocardiography revealed fibrotic changes of the
aortic valve. She developed and was treated for arterial
hypertension. At the age of 40 she had prolonged post-
apendectomy recovery due to sepsis and newly diagnosed
mild thrombocytopenia (100,000/mm3). Physical exami-
nation at that time showed no organomegaly. Sternal
puncture was performed in local hospital, interpreted as
unremarkable with no characteristic pathology found.
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Fig. 1. Echocardiography of aortal valve.
Fig. 2. Typical Gaucher cells in bone marrow aspirate (clockwise
from top left: May-Grünwald-Giemsa staining, cytochemical
staining – alpha naphthyl acetate esterase, immunocytochemical
staining for HLA-DR and CD68).
Fig. 3. Magnetic Resonance Imaging (MRI) findings
of bone involvement.
The patient was followed up for possible autoimmune
thrombocytopenia, with no requirement for treatment.
Despite medical treatment and close follow up, at the age
of 60 she presented with heart failure (NYHA III). At
that time echocardiography showed severe fibrosed aor-
tic valve stenosis with a maximum AV gradient of 70
mmHg and concentric left ventricular hypertrophy (Fig-
ure 1). Valvuloplasty was planned, but was contraindi-
cated due to severe thrombocytopenia (30,000/mm3).
Anemia (Hb 7.5 g/dL) and leukopenia (2,500/mm3) were
also noted, for the first time, as well as mild splenome-
galy on physical examination. She also had elevated
blood concentrations of ferritin and angiotensin convert-
ing enzyme (ACE) with increased liver function tests and
erythrocyte sedimentation rate. Bone marrow aspiration
was performed again, this time in our institution. A sig-
nificant number of macrophages/histiocytes with a small
and single nucleus in each cell were found; with pale blue
to gray cytoplasm and a striated pattern resembling
wrinkled tissue paper, typical for Gaucher cells (Figure
2). The diagnosis of Gaucher’s disease was confirmed by
enzyme activity assay, which showed low b-glucocerebro-
sidase activity. (20% of normal enzyme activity). Molecu-
lar analysis (direct sequencing) showed the patient to be
homozygous for the G377S mutation. Skeletal survey
showed severe bone disease. A plain radiograph revealed
typical Erlenmeyer flask deformity in both distal femurs,
and bone densitometry of the lumbar spine and at the
femoral neck was 80% of that expected for her age. Mag-
netic resonance imaging showed severe bone marrow in-
filtration (Figure 3) and moderate splenomegaly (Figure
4) with spleen volume of 1830 mL. Enzyme replacement
therapy (imiglucerase 60 U/kg every two weeks) was
promptly initiated. Patient’s response to treatment was
rapid and sustained – she promptly became transfusion
independent and presently, 6 months after treatment
start, remains so. Hemoglobin levels increased to 10
g/dL, platelet numbers recovered to 100,000/mm3, and
normalisation of both leukocyte and liver function tests
was also observed.
Discussion
This case of a patient with Gaucher’s disease shows
not only that this lysosome storage disorder can have
many faces, but once again underlines the importance of
collaboration between medical specialists of different
profiles in establishing accurate diagnosis on time. The
role of an experienced cytopathologist was decisive for es-
tablishing GD diagnosis in our patient, as it has certainly
been the case in many other patients, especially those
with mild forms of Gaucher’s disease.
Although uncommon, cardiac involvement in Gau-
cher’s disease has been reported, affecting the pericar-
dium22,23 and myocardium24–27, potentially causing re-
strictive cardiomiopathy. Several case reports19–21 des-
cribed calcifications in aortic and mitral valves as well as
valvular apparatus, with subsequent aortic and mitral
stenosis. All these patients were homozygous for the
D409H mutation, which is associated with cardiovascu-
lar valvular disease in the 3c GD clinical form, in which
neurological involvement includes only oculomotor apra-
xia. In these deffective valves, Gaucher cells have been
identified21,28, and are postulated to play a role in the val-
vular calcification pathogenesis. Not infrequently, Gau-
cher’s disease is diagnosed in adult, even geriatric popu-
lation; The Gaucher Registry shows that 7% of the pa-
tients are 50 and over29, and often with a significant gap
between the initial onset of symptoms and time of diag-
nosis, which is reported to be 13 years in a 2004 survey
among patients from Scandinavia30.
Our patient was diagnosed GD at the age of 60, after
developing severe aortic stenosis, at that time already
with severe bone infiltration, severe thrombocytopenia,
anemia and leukopenia, and moderate splenomegaly.
G377S mutation, found in our patient, is a rare muta-
tion, described before as a 'dosage effect’ allele, where
homozygosity for the mutation appeared to result in type
1 while compound heterozygosity with a null allele leads
to type 3 phenotype31. This mutation has generally been
reported as a 'mild’ mutation32, because of the finding
that homoallelic patients were essentially asymptomatic
or had mild disease. Our patient, also homozygous for
G377S mutation, has a severe form of type 1 GD, with
rare cardiac valve involvement – which, based on its
early onset and absence of any other known predisposing
pathology, we suspect is related to Gaucher’s disease. To
our knowledge, this is a previously unreported clinical
presentation for this mutation. Furthermore, this case
proves that patients with the same genotype can have
different phenotypes, emphasizing the influence of other
genetic and/or environmental factors.
Z. Peri} et al.: Gaucher’s Disease – G377S Mutation, Coll. Antropol. 34 (2010) 1: 275–278
277
Fig. 4. Magnetic Resonance Imaging (MRI) finding of
splenomegaly.
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NEOBI^NA KLINI^KA SLIKA GAUCHEROVE BOLESTI: FIBROZA AORTNOG ZALISTKA
KOD BOLESNICE HOMOZIGOTNE ZA RIJETKU G377S MUTACIJU
S A @ E T A K
Gaucherova se bolest (GB) mo`e prezentirati raznolikom klini~kom slikom, ali rijetko zahva}a kardiovaskularni
sustav. U posljednjih je 25 godina genetski poreme}aj u podlozi ove metaboli~ke bolesti dobro istra`en, s gotovo 300
identificiranih mutacija u genu za lizosomski enzim glukocerebrozidazu. Ipak, jasne genotipsko-fenotipske korelacije,
potvr|ene su samo za naj~e{}e mutacije. Kod na{e pacijentice, patolo{ke promjene na aortnom sr~anom zalistku otkri-
vene su prvi put u dobi od 30 godina. Usprkos redovitom pra}enju, bolesnica se u dobi od 60 godina javlja s klini~kom
slikom te{kog zatajenja srca (NYHA III). Tada u~injeni UZV srca poka`e te{ku aortnu stenozu. Planirani operacijski
zahvat zamjene aortne valvule kontraindicira se, zbog progresije trombocitopenije, dotad smatrane autoimunog po-
rijekla. Tada se prvi put zamijete i anemija te leukopenija. MR ~itavog tijela pokazuje uve}anu slezenu, te difuznu
infiltraciju ko{tane sr`i. Citolo{kom se punkcijom ko{tane sr`i otkriju tipi~ne Gaucherove stanice, a nalaz sni`ene
aktivnosti enzima glukocerebrozidaze potvrdi dijagnozu. Genetskom se analizom ustanovi da je pacijentica homozigot
za G377S mutaciju. Prema dosada{njim spoznajama, samo je homozigotnost za D409H mutaciju povezivana s kardio-
vaskularnim oblikom GB, klini~ki tipom 3c. G377S mutacija, prona|ena kod na{e pacijentice, opisivana je dosad kao
»blaga« mutacija, zbog nalaza da se kod homozigota javlja asimptomatski ili blagi oblik bolesti. Me|utim, na{a pa-
cijentica, tako|er homozigot za G377S mutaciju, ima uznapredovali oblik tipa 1 GB, s rijetkim zahva}anjem aortnog
zalistka, {to je, prema na{im saznanjima, jo{ neopisana klini~ka slika uz ovu mutaciju. Ovaj slu~aj jo{ jednom potvr|uje
utjecaj i drugih genetskih i/ili okoli{nih faktora na klini~ku prezentaciju Gaucherove bolesti.
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